Skip to main content
Paul Watkins, MD, Gastroenterology, Chapel Hill, NC, University of North Carolina Hospitals

PaulBWatkinsMD

Gastroenterology • Chapel Hill, NC

Howard Q Ferguson Distinguished Professor, Director, Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill

Join to view full profile

Dr. Watkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Watkins' full profile

Already have an account?

Summary

  • I am a board certified gastroenterologist specializing in liver diseases, particularly drug-induced liver injury.

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Gastroenterology, 1982 - 1985
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1979 - 1982
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1979

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1999 - 2025
  • MI State Medical License
    MI State Medical License 1986 - 2005
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Agilent Thought Leader Award 2015
  • Rawls Palmer Innovation in Medicine Award 2015
  • Elected Fellow of the AASLD American Association for the Study of Liver Diseases, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Review Post Screen Advancing Nonclinical Innovation and Safety in Pharmaceutical Testing  
    Michael N Liebman, Elizabeth J Baker, Paul B Watkins, ScienceDirect
  • A Rapid Method to Estimate Hepatocyte Loss Due to Drug‐Induced Liver Injury  
    Paul Watkins, MD, Clinical Pharmacology & Therapeutics
  • Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? ‐ an International Transporter Consortium Perspective  
    Paul Watkins, MD, Clinical Pharmacology & Therapeutics

Press Mentions

  • First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
    First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA ReviewOctober 27th, 2020
  • FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations
    FDA Review of Approved Drug, Ubrogepant, Included DILIsym SimulationsSeptember 2nd, 2020
  • U.S. FDA Renews Annual DILIsym Software Licenses
    U.S. FDA Renews Annual DILIsym Software LicensesMay 6th, 2020
  • Join now to see all

Grant Support

  • Unc-Duke Collaborative Clinical Pharmacology Postdoctoral Training ProgramNational Institute Of General Medical Sciences2011
  • Drug-Induced Liver Injury Network (DILIN)National Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
  • UNC Clinical Translation Science Award-T32 Program (TL1)National Center For Research Resources2008
  • UNC Clinical Translation Science Award-K12 Scholars Program (KL2)National Center For Research Resources2008
  • Toxicogenomics Of Acetaminophen Hepatotoxicity- Rechallenge ProtocolNational Center For Research Resources2008
  • Toxicogenomics Of Acetaminophen HepatotoxicityNational Center For Research Resources2008
  • Acetaminophen (Tylenol?) Induced Human Lymphocyte ToxicityNational Center For Research Resources2008
  • Effect Of Acetaminophen (TYLENOL) On Human LymphocytesNational Center For Research Resources2007–2008
  • Environmental Polymorphisms RegistryNational Center For Research Resources2006–2008
  • A Multicenter, Longitudinal Study Of Drug And CAM Induced Liver InjuryNational Center For Research Resources2005–2008
  • Gene Expression And AcetaminophenNational Center For Research Resources2007
  • Hepatoxicity Clincal Research NetworkNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2007
  • Furanocoumarins And Drugs Effect On CYP3A4National Institute Of General Medical Sciences1999–2007
  • Toxicogenomics Of Acetaminophen ToxicityNational Center For Research Resources2005–2006
  • Drug Induced Liver Injury Network-Idiosyncratic Liver InjuryNational Center For Research Resources2005–2006
  • Role Of Cytochrome P450 3A5 Genotype Upon Fluconazole/MidazolamNational Center For Research Resources2004–2006
  • General Clinical Research Centers Annual MeetingNational Center For Research Resources2002–2006
  • Genetic Database For Genetic Polymorphisms Implicated In Drug MetabolismNational Center For Research Resources2005
  • Fc-Free Grapefruit Juice On The Oral Clearance Of Felodipine And CyclosporinNational Center For Research Resources2004–2005
  • Cytochrome P450 3A5 Genotype With Measures Of Blood Pressure And CardiovascularNational Center For Research Resources2004
  • Genetic Factors And Autoantibodies In Drug Induced DiseaseNational Center For Research Resources1998–2002
  • 13C Erythromycin Breath Test To Determine Drug DosagesNational Center For Research Resources1998–2002
  • Effect Of Grapefruit Juice &Seville Orange Juice On Felodipine DispositionNational Center For Research Resources1999–2000
  • P450 Activity And Intestinal Gene Expression Predicts Tacrolimus BioavailabilityNational Center For Research Resources1998–2000
  • Grapefruit Juice Component Responsible For Enhancing Felodipine BioavailabilityNational Center For Research Resources1998–2000
  • Cyclosporin A Bioavailability From Hepatic &Enteric P450 3A4 Catalytic ActivityNational Center For Research Resources1998–2000
  • Diet &Medications On Expression Of CYP3A4 &Cyp3a5 In Intestinal MucosaNational Center For Research Resources1996–2000
  • Furanocoumarins And Drugs Effect On CYP3A4National Institute Of General Medical Sciences1998
  • Predicting Cyclosporin A Bioavailability From Hepatic And Enteric P450 3A4National Center For Research Resources1997
  • Genetic Factors And Auto-Antibodies In Drug Induced DiseaseNational Center For Research Resources1997
  • Component Grapefruit Juice Which Enhances Bioavailability Of FelodipineNational Center For Research Resources1997
  • CYP3A4 And CYP3A5 In IntestineNational Institute Of General Medical Sciences1994–1997
  • Noninvasive Tests Of P450 IIIA Enzymes In ManNational Institute Of Environmental Health Sciences1996
  • Genetic Factors, And Autoantibodies, In Patients With Drug Induced DiseaseNational Center For Research Resources1996
  • Effect Of Oral Ketoconazole Therapy On Pharmokinetics Of Taxol--Pilot StudyNational Center For Research Resources1996
  • Component Grapefruit Juice Responsible For BioavailabilityNational Center For Research Resources1996
  • Regulation Of P-450 III Cytochromes In Liver &IntestineNational Institute Of General Medical Sciences1992–1993
  • Nonvasive Assays Of P450IIIA Enzymes In ManNational Institute Of Environmental Health Sciences1991
  • Environmental And Genetic Factors Regulating HlpNational Institute Of General Medical Sciences1986–1991

Professional Memberships

Hospital Affiliations

Dr. Paul Watkins, Dr. Paul Watkins, MD, Dr. P Watkins, Dr. Paul B Watkins